Drug Trial Radar · NCT07621601
A Study of HS-20093 in Patients With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)
Last checked: Nov 19, 2026Latest source record: Jun 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
494
Planned (sponsor's estimate)
Start
Jul 31, 2026
Primary completion
Dec 31, 2030
Study completion Dec 31, 2032
Sponsor
- Lead sponsor
- Hansoh BioMedical R&D CompanyIndustry
- Sponsor type
- Industry
- First posted
- Jun 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, open-label, controlled phase III clinical study to evaluate the efficacy and safety of HS-20093- injection versus investigator's choice of chemotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma after progress of first-line standard therapy.
Conditions
- Esophageal Squamous Cell Carcinoma (ESCC)
Interventions
HS-20093 for InjectionDrug
The patient will receive treatment with HS-20093.
Irinotecan; Paclitaxel; DocetaxelDrug
The patient will receive treatment with Irinotecan or Paclitaxel or Docetaxel
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survival (OS)Time frame: Approximately 4 years after the first patient with first dose
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.